Mumbai, Jan. 31 -- Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review.

The company's Generics business, comprising of APIs & generic formulations, has recorded revenues of Rs 686 crore in Q3 FY25, down 2% YoY.

Biocon Biologics, which houses Biocon's biosimilars business, has reported 8% YoY fall in revenue to Rs 2,289 crore.

Syngene, which is the Research services division of Biocon, has registered 11% increase in revenue to Rs 944 crore in the third quarter as compared with the same period last year.

The company's Research & Development expenses added up to Rs 199 crore in Q3 FY25, down 40% YoY.

EBITDA declined by 47% to Rs 787 crore in Q3 FY25 from Rs 1,492 crore in Q3 FY24.

Profit before tax i...